Lipoprotein(a) Screening and Management
Lipoprotein(a) should be measured once in a lifetime and does not need to be repeated, as it is genetically determined and remains stable throughout life. Currently, no proven therapies specifically lower Lp(a) to reduce cardiovascular outcomes, but several agents can reduce Lp(a) levels while we await definitive evidence from ongoing clinical trials.
How Often to Check Lp(a)
Measure Lp(a) once in every adult's lifetime as part of initial lipid screening 1. The 2021 Canadian Cardiovascular Society Guidelines provide the strongest and most recent recommendation on this point, stating explicitly that "Lp(a) testing does not need to be repeated if it has previously been measured (ie, in childhood or early adulthood)" 2.
Priority Populations for Testing
While universal screening is increasingly recommended, prioritize measurement in:
- Adults with family history of premature atherosclerotic cardiovascular disease
- Personal history of atherosclerotic cardiovascular disease
- Family history of high Lp(a)
- Premature cardiovascular disease without evident risk factors
- Recurrent or rapidly progressive vascular disease despite optimal therapy 2
Clinical Thresholds
- Lp(a) ≥50 mg/dL (≥125 nmol/L) enhances atherosclerotic cardiovascular disease risk 2
- The relationship between Lp(a) and cardiovascular risk is continuous and dose-dependent, without a clear threshold 1
- Some guidelines use ≥30 mg/dL (≥75 nmol/L) as the 75th percentile cutoff for elevated risk 3
What Can Lower Lp(a)
Critical Caveat: No Proven Cardiovascular Benefit Yet
It is not yet known whether reducing Lp(a) reduces atherosclerotic cardiovascular disease risk 2. This is the most important limitation in current Lp(a) management. While several therapies lower Lp(a) levels, no randomized controlled trial has demonstrated that specifically lowering Lp(a) leads to reductions in cardiovascular outcomes 1.
Currently Available Therapies
Commonly used lipid-lowering therapies (statins and ezetimibe) do not appreciably lower Lp(a) levels 1. In fact, statins may inconsistently cause Lp(a) elevation 4.
Therapies That Do Lower Lp(a):
PCSK9 Inhibitors (most relevant for clinical practice):
- Provide substantial Lp(a) lowering (approximately 20-30%)
- Already approved for LDL-cholesterol lowering
- Post-hoc analyses suggest benefit in patients with elevated Lp(a), though this may be independent of Lp(a) lowering 1
- Consider in secondary prevention patients with high Lp(a) who remain at high risk despite statin therapy
Niacin (Extended-Release):
- Reduces Lp(a) by 30-35% 4
- Currently the most recommended drug specifically for Lp(a) reduction 4
- Poorly tolerated by many patients
- No proven cardiovascular benefit in modern trials
Lipoprotein Apheresis:
- Reduces Lp(a) up to 80% 4
- FDA-approved indication for high-risk patients with familial hypercholesterolemia and documented coronary or peripheral artery disease whose Lp(a) ≥60 mg/dL (~150 nmol/L) and LDL-C ≥100 mg/dL on maximally tolerated therapy 5
- Expensive and impractical for most patients
- Observational data suggest cardiovascular benefit 4
Emerging Targeted Therapies (Not Yet Available)
Antisense Oligonucleotides and siRNA-based agents show promise:
- Reduce Lp(a) by up to 90% 6, 7
- Phase 3 cardiovascular outcomes trials currently underway 6, 7
- May become first-line specific Lp(a)-lowering therapy if trials demonstrate cardiovascular benefit
Current Management Strategy
For patients with elevated Lp(a) ≥50 mg/dL (≥125 nmol/L):
Intensify management of all other modifiable cardiovascular risk factors 1:
- More aggressive LDL-cholesterol lowering (target <70 mg/dL or <1.8 mmol/L)
- Earlier initiation of statin therapy
- Blood pressure control
- Smoking cessation
- Weight management
- Diabetes management
Consider coronary artery calcium scoring for further risk stratification in primary prevention, especially when treatment decisions remain uncertain 2
In secondary prevention with high Lp(a): Consider adding PCSK9 inhibitor to statin therapy for more intensive LDL-lowering and potential Lp(a) reduction 1
Cascade screening: Test first-degree relatives of patients with elevated Lp(a) 5
Important Clinical Pitfall
Do not repeat Lp(a) testing unless the patient is enrolled in a clinical trial or being considered for apheresis. Lp(a) levels are genetically determined and stable over time. Repeated testing wastes resources and does not change management 2, 1.
The key message: Measure once, manage cardiovascular risk aggressively, and await results of ongoing trials for specific Lp(a)-lowering therapies.